Analystreport

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.

Xenon Pharmaceuticals Inc. - Common Shares  (XENE) 
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.xenon-pharma.com